Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Ligand Pharmaceuticals Incorporated (LGND)

Healthcare Biotechnology

287.50 $

-3.0% vs. previous close

Closing price · As of: 31. Jul 2026

Ligand Pharmaceuticals Incorporated (LGND) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Total Assets" came in at 1,532 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow

Annual Quarterly

All figures in millions of USD.

Balance Sheet LGND
Tick rows to compare them in a chart (up to 4)	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26
Total Assets	758	769	787	914	866	955	942	905	949	1,477	1,561	1,532
Current Assets	277	254	237	369	312	309	332	309	353	754	832	865
Cash	28	19	23	50	18	64	72	48	68	139	175	115
Cash & Short-Term Investments	219	191	170	311	227	220	256	209	255	665	734	779
Receivables	28	36	39	28	37	42	42	43	42	58	61	55
Inventory	27	25	24	21	14	13	14	12	13	12	9.1	13
Property, Plant & Equipment	11	–	–	–	–	–	–	–	–	–	–	–
Goodwill	106	104	103	105	105	105	105	102	102	102	102	102
Intangible Assets	336	321	300	291	283	275	267	258	250	234	422	411
Total Liabilities	93	101	86	107	91	114	111	110	120	527	543	535
Current Liabilities	29	16	17	18	19	25	37	59	65	31	37	41
Short-Term Debt	0.7	0.5	0.4	1.0	1.2	1.1	1.3	0.9	1.1	2.2	1.1	1.1
Accounts Payable	9.6	2.5	2.4	1.9	1.8	4.7	5.2	5.4	8.6	28	3.2	5.3
Long-Term Debt	–	–	–	–	–	–	–	–	–	445	446	447
Shareholders' Equity	665	668	701	807	775	841	830	796	829	950	1,017	997
Retained Earnings	495	485	503	589	537	530	499	457	461	578	608	595
Shares Outstanding	18	17	18	18	18	18	19	19	20	20	21	20

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Cookie settings